Individual isotoxic radiation dose escalation based on V20 and advanced technologies benefits unresectable stage III non-small cell lung cancer patients treated with concurrent chemoradiotherapy: long term follow-up

Under the assumption that the highest therapeutic ratio could be achieved by increasing the total tumor dose (TTD) to the limits of normal tissues, the phase I trial was conducted in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy, to determi...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ming, Wang, Zhongtang, Zhou, Tao, Zhou, Antang, Zhao, Qian, Li, Hongsheng, Sun, Hongfu, Huang, Wei, Li, BaoSheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584295/
https://www.ncbi.nlm.nih.gov/pubmed/28881694
http://dx.doi.org/10.18632/oncotarget.16288

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584295/
https://www.ncbi.nlm.nih.gov/pubmed/28881694
http://dx.doi.org/10.18632/oncotarget.16288

Ejemplares similares